EP3755312A4 - DOSAGE FORMS AND PROCESSES FOR ENANTIOMER ENHANCED OR PURE BUPROPION - Google Patents

DOSAGE FORMS AND PROCESSES FOR ENANTIOMER ENHANCED OR PURE BUPROPION Download PDF

Info

Publication number
EP3755312A4
EP3755312A4 EP19756920.5A EP19756920A EP3755312A4 EP 3755312 A4 EP3755312 A4 EP 3755312A4 EP 19756920 A EP19756920 A EP 19756920A EP 3755312 A4 EP3755312 A4 EP 3755312A4
Authority
EP
European Patent Office
Prior art keywords
methods
dosage forms
enantiomerically enriched
pure bupropion
obtaining enantiomerically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19756920.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3755312A1 (en
Inventor
Herriot TABUTEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axsome Therapeutics Inc
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of EP3755312A1 publication Critical patent/EP3755312A1/en
Publication of EP3755312A4 publication Critical patent/EP3755312A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19756920.5A 2018-02-23 2019-02-25 DOSAGE FORMS AND PROCESSES FOR ENANTIOMER ENHANCED OR PURE BUPROPION Pending EP3755312A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862634718P 2018-02-23 2018-02-23
US201962794469P 2019-01-18 2019-01-18
US201962809480P 2019-02-22 2019-02-22
PCT/US2019/019445 WO2019165379A1 (en) 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion

Publications (2)

Publication Number Publication Date
EP3755312A1 EP3755312A1 (en) 2020-12-30
EP3755312A4 true EP3755312A4 (en) 2022-03-16

Family

ID=67688503

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19756920.5A Pending EP3755312A4 (en) 2018-02-23 2019-02-25 DOSAGE FORMS AND PROCESSES FOR ENANTIOMER ENHANCED OR PURE BUPROPION

Country Status (19)

Country Link
EP (1) EP3755312A4 (https=)
JP (3) JP2021513998A (https=)
KR (3) KR20230075531A (https=)
CN (2) CN112087999A (https=)
AU (3) AU2019223187B2 (https=)
BR (1) BR112020017179A2 (https=)
CA (1) CA3092076A1 (https=)
CL (1) CL2020002166A1 (https=)
CR (1) CR20200415A (https=)
EC (1) ECSP20060179A (https=)
IL (2) IL276871B2 (https=)
MA (1) MA51914A (https=)
MX (2) MX2020008704A (https=)
MY (1) MY202993A (https=)
NI (1) NI202000056A (https=)
NZ (1) NZ767378A (https=)
PE (1) PE20211752A1 (https=)
SG (1) SG11202008056SA (https=)
WO (1) WO2019165379A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3092076A1 (en) * 2018-02-23 2019-08-29 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
KR20220066930A (ko) * 2019-09-20 2022-05-24 액섬 테라퓨틱스, 인크. 에난티오머적으로 풍부한 또는 순수한 부프로피온을 위한 제형 및 방법
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US12156914B2 (en) * 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
WO2025259728A1 (en) * 2024-06-13 2025-12-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501890A (ja) * 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（＋）−ビュープロピオンの薬学的使用
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
ME00391B (me) * 2003-08-08 2011-10-10 Biovail Laboratories Int Srl Tableta bupropion hidrohlorida sa modifikovanim otpuštanjem
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US9198905B2 (en) * 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US10080727B2 (en) * 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
WO2015095713A1 (en) * 2013-12-20 2015-06-25 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
CA3092076A1 (en) * 2018-02-23 2019-08-29 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects

Also Published As

Publication number Publication date
MX2023009281A (es) 2023-08-17
CR20200415A (es) 2021-02-03
NZ767378A (en) 2024-03-22
JP2021513998A (ja) 2021-06-03
WO2019165379A1 (en) 2019-08-29
KR20230075531A (ko) 2023-05-31
KR20240091043A (ko) 2024-06-21
ECSP20060179A (es) 2020-12-31
MA51914A (fr) 2020-12-30
NI202000056A (es) 2021-01-11
IL276871A (en) 2020-10-29
AU2022204521A1 (en) 2022-07-21
EP3755312A1 (en) 2020-12-30
CA3092076A1 (en) 2019-08-29
AU2019223187B2 (en) 2022-07-28
CL2020002166A1 (es) 2020-10-23
AU2019223187A1 (en) 2020-09-17
BR112020017179A2 (pt) 2020-12-22
JP2024075655A (ja) 2024-06-04
MX2020008704A (es) 2020-12-07
IL276871B2 (en) 2024-11-01
AU2022204521B2 (en) 2024-09-05
MY202993A (en) 2024-05-31
IL313368A (en) 2024-08-01
JP2022153638A (ja) 2022-10-12
CN112087999A (zh) 2020-12-15
PE20211752A1 (es) 2021-09-06
SG11202008056SA (en) 2020-09-29
IL276871B1 (en) 2024-07-01
CN120827545A (zh) 2025-10-24
KR20210003091A (ko) 2021-01-11
AU2024205858A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
MA51914A (fr) Formes posologiques et procédés pour obtenir du bupropion énantiomériquement enrichi ou pur
EP3847818A4 (en) A VIDEO ENCODER, A VIDEO DECODER, AND CORRESPONDING METHODS
EP3987794A4 (en) ENCODER, DECODER AND METHOD THEREOF
MA71705A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
EP3861743A4 (en) VIDEO DECODER AND METHOD
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
EP4070549A4 (en) ENCODER, DECODER AND RELATED METHODS AND DEVICE
EP3975717C0 (en) WATER TREATMENT PROCESS AND COMPOSITION
EP3556222C0 (en) SYSTEM AND METHOD FOR PRODUCING A SUGAR STREAM
EP3478753C0 (en) CELLULOSE-BASED FILM STRUCTURE AND ITS PRODUCTION PROCESS
EP3552834A4 (en) FRAME PLATE AND MANUFACTURING METHOD THEREOF
EP3532042A4 (en) METHOD FOR IMPROVING SYNAPTOGENESIS AND NEURITOGENESIS
EP3864715A4 (en) DISPLAY SUBSTRATE, DISPLAY APPARATUS AND METHOD OF MAKING DISPLAY SUBSTRATE
EP3710422C0 (en) PROCESS FOR PREPARING ENANTIOMERICALLY AND DIASTEROMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES
EP4026337A4 (en) ENCODER, DECODER AND METHOD THEREOF
EP3461088A4 (en) Method and apparatus for determining video quality, and method and apparatus for locating network fault
EP3982633A4 (en) VIDEO ENCODER, VIDEO DECODER AND CORRESPONDING METHOD
EP4070551A4 (en) ENCODER, DECODER AND METHOD THEREOF
EP3896974A4 (en) Video encoder, video decoder, and corresponding method
EP3960868A4 (en) Polyhydroxyalkanoic acid and method for producing same
EP3868110A4 (en) CODERS, DECODERS AND RELATED METHODS FOR UNBLOCKING FILTER ADAPTATION
EP3527191A4 (en) COMPOSITE DENTAL RESIN MATERIAL, METHOD FOR PRODUCING COMPOSITE DENTAL RESIN MATERIAL, AND POLYARYLETHERCETONE RESIN FOR PRODUCING COMPOSITE DENTAL RESIN MATERIAL
EP3781137A4 (en) HUMIDITY RESISTANT PROBIOTIC GRANULE AND ITS PRODUCTION PROCESSES
EP4076881C0 (de) Vorrichtung zur herstellung von betonsteinen
EP3837845A4 (en) VIDEO ENCODER, VIDEO DECODER AND RELEVANT PROCEDURE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200921

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TABUTEAU, HERRIOT

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40041795

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20220216

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20220210BHEP

Ipc: A61P 25/30 20060101ALI20220210BHEP

Ipc: A61P 25/28 20060101ALI20220210BHEP

Ipc: A61P 25/24 20060101ALI20220210BHEP

Ipc: A61P 25/18 20060101ALI20220210BHEP

Ipc: A61P 25/00 20060101ALI20220210BHEP

Ipc: A61K 31/485 20060101ALI20220210BHEP

Ipc: A61K 31/137 20060101AFI20220210BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230306

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AXSOME THERAPEUTICS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20241014